Xeris Biopharma Holdings (XERS) Short term Debt (2023 - 2025)

Xeris Biopharma Holdings' Short term Debt history runs 3 years deep, the most recent figure standing at $12.0 million for Q1 2025.

• Quarterly Short term Debt rose 1071.3% year-over-year to $12.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $12.0 million (up 1071.3% YoY) and the FY2024 annual result came in at $15.1 million, changed N/A from the prior year.
• Short term Debt was $12.0 million for Q1 2025 at Xeris Biopharma Holdings, down from $15.1 million in the prior quarter.
• Across five years, Short term Debt topped out at $17.5 million in Q3 2023 and bottomed at $420000.0 in Q2 2024.
• A 3-year average of $11.6 million and a median of $15.0 million in 2023 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt tumbled 97.48% — and 2025, when it jumped 1071.3%.
• Xeris Biopharma Holdings' Short term Debt stood at $17.5 million in 2023, then dropped by 13.79% to $15.1 million in 2024, then declined by 20.81% to $12.0 million in 2025.
• Business Quant data shows XERS's Short term Debt at $12.0 million in Q1 2025, $15.1 million in Q4 2024, and $15.1 million in Q3 2024.